Vera Therapeutics (VERA) News Today $37.48 -0.45 (-1.19%) Closing price 04:00 PM EasternExtended Trading$37.91 +0.43 (+1.15%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Vera Therapeutics (NASDAQ:VERA) Trading Up 4.9% - Still a Buy?Vera Therapeutics (NASDAQ:VERA) Stock Price Up 4.9% - Here's What HappenedJanuary 29 at 4:15 PM | marketbeat.comSG Americas Securities LLC Increases Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)SG Americas Securities LLC lifted its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 116.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,270 shares of the company's stock after purchasing an adJanuary 29 at 3:15 AM | marketbeat.comVera started at buy by Goldman Sachs, atacicept potential citedJanuary 28 at 8:56 PM | msn.comVera Therapeutics (NASDAQ:VERA) Shares Gap Up - Here's What HappenedVera Therapeutics (NASDAQ:VERA) Shares Gap Up - Time to Buy?January 28 at 12:49 PM | marketbeat.comThe Goldman Sachs Group Initiates Coverage on Vera Therapeutics (NASDAQ:VERA)The Goldman Sachs Group began coverage on Vera Therapeutics in a report on Tuesday. They set a "buy" rating and a $58.00 price objective for the company.January 28 at 9:07 AM | marketbeat.comVera Therapeutics initiated with a Buy at Goldman SachsJanuary 27 at 10:05 PM | markets.businessinsider.comBiotech Market Forecast: Top Trends for Biotech in 2025January 24, 2025 | msn.comVera Therapeutics: Promising Clinical Progress and Strategic Positioning Drive Buy RatingJanuary 24, 2025 | markets.businessinsider.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives $63.50 Average PT from AnalystsJanuary 24, 2025 | americanbankingnews.comBrokers Issue Forecasts for VERA FY2025 EarningsVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Vera Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. StavropoulosJanuary 23, 2025 | marketbeat.comTD Cowen Sticks to Its Buy Rating for Vera Therapeutics (VERA)January 22, 2025 | markets.businessinsider.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of "Buy" from AnalystsShares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have received a consensus rating of "Buy" from the nine research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, six have issued a buy ratingJanuary 21, 2025 | marketbeat.comVera Therapeutics Releases Updated Corporate Presentation Following J.P. Morgan Healthcare ConferenceJanuary 20, 2025 | americanbankingnews.comVera Therapeutics: Strategic Licensing and Promising Clinical Data Justify Buy RatingJanuary 15, 2025 | markets.businessinsider.comEvercore ISI Sticks to Its Buy Rating for Vera Therapeutics (VERA)January 14, 2025 | markets.businessinsider.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 14, 2025 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Shares Gap Down Following Insider SellingVera Therapeutics (NASDAQ:VERA) Shares Gap Down on Insider SellingJanuary 13, 2025 | marketbeat.comVera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL InhibitorJanuary 13, 2025 | finance.yahoo.comVera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells $730,450.00 in StockVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 17,500 shares of the business's stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the transaction, the chief executive officer now owns 143,603 shares in the company, valued at $5,993,989.22. The trade was a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.January 10, 2025 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Stock Price Down 7.3% - Should You Sell?Vera Therapeutics (NASDAQ:VERA) Stock Price Down 7.3% - Should You Sell?January 10, 2025 | marketbeat.comVera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 7, 2025 | globenewswire.comGeode Capital Management LLC Buys 20,223 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Geode Capital Management LLC lifted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 2.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,004,665 shares of the company's stock after acquiringDecember 24, 2024 | marketbeat.comPromising Developments in VYNE Therapeutics’ VYN202 Support Buy RatingDecember 23, 2024 | markets.businessinsider.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Barclays PLCBarclays PLC increased its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 94.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 85,395 shares of the company's stock after buying an additioDecember 23, 2024 | marketbeat.comVera Therapeutics: Strong Data In IgAN, But We May Be Too LateDecember 22, 2024 | seekingalpha.comVera Therapeutics, Inc. (NASDAQ:VERA) CEO Sells $753,725.00 in StockVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 17,500 shares of the firm's stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total value of $753,725.00. Following the completion of the sale, the chief executive officer now directly owns 85,942 shares in the company, valued at approximately $3,701,521.94. The trade was a 16.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.December 20, 2024 | marketbeat.comWellington Management Group LLP Decreases Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)Wellington Management Group LLP lowered its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 82.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,071 shares of the compaDecember 20, 2024 | marketbeat.comState Street Corp Sells 331,746 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)State Street Corp decreased its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 15.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,823,807 shares of the company's stock after selling 331,746 shares during the quarter. StateDecember 17, 2024 | marketbeat.comLord Abbett & CO. LLC Acquires 124,197 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Lord Abbett & CO. LLC grew its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 41.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 426,014 shares of the company's stock aDecember 16, 2024 | marketbeat.comMarshall Fordyce Sells 17,500 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) StockVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 17,500 shares of the company's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $46.94, for a total value of $821,450.00. Following the completion of the transaction, the chief executive officer now directly owns 85,942 shares in the company, valued at $4,034,117.48. This trade represents a 16.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.December 13, 2024 | marketbeat.comY Intercept Hong Kong Ltd Has $1.37 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Y Intercept Hong Kong Ltd grew its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 283.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,911 shares of the company's stock after purchasing an aDecember 12, 2024 | marketbeat.comCarisma Therapeutics (CARM) Receives a Hold from Evercore ISIDecember 11, 2024 | markets.businessinsider.comVera Therapeutics (VERA) Receives a Buy from TD CowenDecember 11, 2024 | markets.businessinsider.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 9, 2024 | globenewswire.comPier Capital LLC Invests $4.57 Million in Vera Therapeutics, Inc. (NASDAQ:VERA)Pier Capital LLC acquired a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 103,463 shares of the company's stock, valued at approximately $4December 8, 2024 | marketbeat.comPoint72 Asset Management L.P. Raises Position in Vera Therapeutics, Inc. (NASDAQ:VERA)Point72 Asset Management L.P. lifted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 44.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 171,573 shares of the company's stock after purchDecember 8, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Has $15.99 Million Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)Charles Schwab Investment Management Inc. lifted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 3.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 361,805 shares of the company's stock aDecember 8, 2024 | marketbeat.comVerition Fund Management LLC Invests $1.91 Million in Vera Therapeutics, Inc. (NASDAQ:VERA)Verition Fund Management LLC bought a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 43,210 shares of the company's stock, valued at aDecember 6, 2024 | marketbeat.comReadystate Asset Management LP Cuts Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)Readystate Asset Management LP lowered its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 93.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 47,683 shares of the company's stock after sellinDecember 5, 2024 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Fmr LLCFmr LLC lessened its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 0.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,785,284 shares of the company's stock after selling 16,654 sharDecember 5, 2024 | marketbeat.comHighVista Strategies LLC Raises Stake in Vera Therapeutics, Inc. (NASDAQ:VERA)HighVista Strategies LLC grew its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 140.2% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 22,010 shares of the company's stock after buying an additional 12,848 shares during the period. HigDecember 3, 2024 | marketbeat.comCinctive Capital Management LP Purchases 13,728 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Cinctive Capital Management LP raised its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 39.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 48,500 shares of the companyDecember 3, 2024 | marketbeat.comIntech Investment Management LLC Purchases New Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)Intech Investment Management LLC acquired a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 10,737 shares of the company's stock, valued at approximately $475,000. Other hedge fundsDecember 3, 2024 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Buy" from AnalystsShares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have been assigned an average recommendation of "Buy" from the ten brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and twoDecember 2, 2024 | marketbeat.comJPMorgan updates its U.S. Analyst Focus List – Adds TPR, ALRM, REGNovember 25, 2024 | msn.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 22, 2024 | globenewswire.comWells Fargo Initiates Coverage of Vera Therapeutics (VERA) with Overweight RecommendationNovember 22, 2024 | msn.comVera Therapeutics (VERA) Gets a Buy from J.P. MorganNovember 21, 2024 | markets.businessinsider.comVera Therapeutics (NASDAQ:VERA) Now Covered by Wells Fargo & CompanyWells Fargo & Company began coverage on shares of Vera Therapeutics in a research note on Thursday. They set an "overweight" rating and a $70.00 price target on the stock.November 21, 2024 | marketbeat.comGSA Capital Partners LLP Trims Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)GSA Capital Partners LLP cut its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 62.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,113 shares of the company's stock after selling 20November 20, 2024 | marketbeat.com Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address VERA Media Mentions By Week VERA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERA News Sentiment▼0.790.74▲Average Medical News Sentiment VERA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERA Articles This Week▼135▲VERA Articles Average Week Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Today Ascendis Pharma A/S News Today Blueprint Medicines News Today BridgeBio Pharma News Today Revolution Medicines News Today Lantheus News Today Legend Biotech News Today Elanco Animal Health News Today Cytokinetics News Today Nuvalent News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERA) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredDonald Trump is about to free crypto from its chains …On October 25th, Juan said Bitcoin would cross $100,000 before the inauguration. Now he thinks it could rea...Weiss Ratings | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrillion-Dollar Crypto PlayPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
